Clinical trial NCT02324335: Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Official title: Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Head and Neck Neoplasms
Mucositis
Keywords: Oral Mucositis
Brilacidin
Chemoradiation
Lead sponsor: Innovation Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2014-12-24
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.

Detailed description: This study will examine whether daily oral rinses with a solution containing brilacidin will prevent the occurrences of OM or lessen the severity of OM if it occurs. Patients will use an oral rinse 3 times daily for up to seven weeks during chemoradiation for head and neck cancer.

Eligibility criteria: Inclusion Criteria:

1. Willing and able to read, understand and sign an informed consent form (ICF)
2. Have recently diagnosed (within previous 6 months) pathologically confirmed, non-metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx that will be treated with CRT therapy as first line non-surgical treatment. Scans (CT, PET, and/or MRI) obtained within 120 days prior to consent for screening can be used to determine the subject's eligibility.
3. Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 Gy to 2.2 Gy with a cumulative radiation dose ≥55 Gy and ≤72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, ventral/lateral tongue, soft palate). \[Note: the independent RTQA consultant must confirm that the planned radiation treatment meets the protocol criteria\]
4. Have a plan to receive a standard cisplatin chemotherapy regimen administered weekly (30-40 mg/m2) or approximately every 21 days (80-100 mg/m2)
5. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. However, potential subjects with an ECOG of 3 may be enrolled provided their condition does not preclude performing the actions required by study participation (e.g., opening medication bottles, swishing the oral rinse and spitting out, completing or participating in completion of daily diaries and FACT-H\&N forms).
6. Have adequate hematopoietic, hepatic, and renal function at a screening visit
7. Urine or serum pregnancy test: negative for female patients of childbearing potential
8. Agree to utilize medically accepted methods of birth control during study participation and for 90 days following the last treatment with study drug if a female subject is of childbearing potential or if a male subject has an opposite sex partner of child bearing potential.
9. Males or females aged ≥18 years on day of consent.

Exclusion Criteria:

1. Has tumor(s) of the lips, sinuses, salivary glands, nasopharynx, glottic larynx, subglottic larynx or unknown primary tumor
2. Has metastatic disease (M1) Stage IV C
3. Has had prior radiation to the head and neck
4. Plan to be treated with cetuximab (Erbitux®)
5. Planned use of cisplatin as induction chemotherapy.
6. Has a history of other malignant tumors within the last 5 years, except non melanoma skin cancer or in situ cervical carcinoma curatively excised
7. Has had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; anticipation of need for major surgical procedure during the course of the study
8. Has incompletely healed sites of dental extractions
9. Has an 12-lead ECG obtained at screening visit which shows medically significant abnormality(ies) (e.g. left bundle branch block, frequent premature ventricular contractions, QTc interval prolongation \> 450 msec for males and \> 470 msec for females)
10. Has untreated hypertension or has hypertension under treatment that meets protocol definitions.
11. Has active infectious disease undergoing systemic treatment excluding oral candidiasis
12. Has oral mucositis (of any severity) prior to initiation of radiation therapy
13. Has a diagnosis of an immunosuppressive illness or a condition requiring chronic immunosuppression
14. Has known seropositivity for HIV or hepatitis C antibody, or known to be hepatitis B surface antigen positive (testing for these serologic markers is not required for enrollment in this protocol)
15. Use of any investigational agent within 30 days of randomization
16. Is pregnant or breastfeeding
17. Has known allergies or intolerance to brilacidin, cisplatin or carboplatin
18. Has inability to give informed consent or comply with study requirements
19. Has any other condition or prior therapy that in the opinion of the Investigator would make the patient unsuitable for the study and/or unable to comply with requirements for follow-up visits.
20. Is unwilling or unable to agree to swish and spit the study oral rinse three times per day during the study period

Primary outcomes:
measure: Incidence of Severe OM During Radiation Therapy in Subjects Receiving a Cumulative IMRT Dose of at Least 55 Gy
timeFrame: 7 weeks
Secondary outcomes:
measure: Duration of Severe Oral Mucositis (WHO Grade ≥3) [Overall Duration]
timeFrame: 11 weeks
measure: Incidence of Severe Oral Mucositis (WHO Grade ≥3) for Subjects Receiving Cisplatin Every 21 Days
timeFrame: 7 weeks
measure: Time to Onset of Severe Oral Mucositis (WHO Grade ≥3)
timeFrame: 7 weeks
Other outcomes:
Locations:
city: Gilbert
country: United States
state: Arizona
city: Lakeland
country: United States
state: Florida
city: Columbus
country: United States
state: Georgia
city: Louisville
country: United States
state: Kentucky
city: Shreveport
country: United States
state: Louisiana
city: Saint Louis
country: United States
state: Missouri
city: Albuquerque
country: United States
state: New Mexico
city: Cheektowaga
country: United States
state: New York
city: Poughkeepsie
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: Stony Brook
country: United States
state: New York
city: Cleveland
country: United States
state: Ohio
city: Toledo
country: United States
state: Ohio
city: Philadelphia
country: United States
state: Pennsylvania
city: Charleston
country: United States
state: South Carolina
city: Milwaukee
country: United States
state: Wisconsin
Study officials:
References: